Glucose-6-Phosphate Dehydrogenase Deficiency and the Benefits of Early Screening

Area of Science:

• Medical Genetics
• Hematology
• Neonatology

Background:

• Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most prevalent enzymopathy globally.
• The enzyme G6PD is critical for protecting red blood cells from oxidative damage.
• Deficiency can cause hemolysis, severe hyperbilirubinemia, and kernicterus, especially in newborns.

Purpose of the Study:

• To highlight the increasing incidence of G6PD deficiency in the US.
• To emphasize the lack of universal screening and risk assessment tools.
• To advocate for mandatory screening to prevent G6PD-related neurotoxicity.

Main Methods:

• Review of existing literature on G6PD deficiency prevalence and consequences.
• Analysis of current screening practices in the United States.
• Discussion of potential screening and risk assessment strategies.

Main Results:

• G6PD deficiency is a significant cause of pathological hyperbilirubinemia.
• Increased migration and intermarriage contribute to its rising prevalence in the US.
• The absence of universal screening poses a risk to infants.

Conclusions:

• Mandatory universal screening for G6PD deficiency is recommended.
• Implementation of surveillance and hospital-based risk assessment tools is essential.
• Early identification and treatment can prevent severe hyperbilirubinemia and neurotoxicity in infants.